Lipocine Inc. (LPCN)

Market Cap	17.74M -8.6%
Revenue (ttm)	2.00M -45.5%
Net Income	-11.43M
EPS	-1.97
Shares Out	8.03M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	74,463
Open	2.140
Previous Close	2.190
Day's Range	2.125 - 2.225
52-Week Range	1.810 - 12.370
Beta	0.46
Analysts	Buy
Price Target	6.00 (+171.49%)
Earnings Date	May 7, 2026

About LPCN

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 14
• Stock Exchange: NASDAQ
• Ticker Symbol: LPCN
• Website: https://www.lipocine.com

Analyst Summary

According to 2 analysts, the average rating for LPCN stock is "Buy." The 12-month stock price target is $6.0, which is an increase of 171.49% from the latest price.

Price Target

$6.0

(171.49% upside)

Analyst Consensus: Buy